<?xml version="1.0" encoding="UTF-8"?>
<p id="p0090">Lots of concerns have been raised about the safety of RAAS inhibitors in COVID-19. ACE inhibitors and angiotensin receptor blockers (ARB) may upregulate of ACE2 thereby increasing susceptibility to the virus and hence may cause more severe infection. On the contrary, there is evidence that these drugs may enhance the protective effect of ACE2 on lung. ACE II may be beneficial in patients with lung injury and withdrawal of RAAS inhibitors in certain high-risk patients with known or suspected Covid-19 may be harmful for the patients.
 <xref rid="bib31" ref-type="bibr">
  <sup>31</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib47" ref-type="bibr">
  <sup>47</sup>
 </xref> The data is currently insufficient to provide any definite recommendation however it is advisable to continue these medications even in children taking them for indications for which the agents are known to be beneficial.
</p>
